Inflammatory mediator synthesis

“Inflammatory mediator synthesis” refers broadly to the **cellular and biochemical processes** by which immune cells produce substances that regulate inflammation. These include cytokines (such as IL‑1β, IL‑6, TNF‑α), lipid-derived molecules (prostaglandins via cyclooxygenase/COX enzymes and leukotrienes via lipoxygenase/LOX), histamine from mast cells, chemokines guiding cell migration, and specialized pro-resolving lipid mediators. The term does **not denote a single molecule or receptor**, but rather encompasses multiple biosynthetic pathways essential for initiating and resolving inflammatory responses. Drugs modulate these processes by inhibiting key enzymes within these pathways—for example, NSAIDs inhibit COX-mediated prostaglandin production[1][2][3]. In summary: “Inflammatory mediator synthesis” is **not** an individual therapeutic target but describes several interconnected biological processes responsible for producing molecules that mediate inflammation. It should be replaced with more precise targets such as “Cyclooxygenase 2,” “Interleukin 6,” etc., when seeking structured information on drug targets.

Other names

Inflammatory mediator synthesis is not a specific molecule, receptor, or protein; it refers to the **biological process** by which various inflammatory mediators are produced.

Mechanisms relate to inhibition of key enzymes—e.g., COX inhibitors block prostaglandin synthesis; LOX inhibitors block leukotriene production. There is no unified mechanism for "inflammatory mediator synthesis" itself.